newsfilter
← Latest News
GlobeNewswire·

The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-'749) for the Treatment of Schizophrenia in Adults

The olanzapine long-acting injectable (TEV-'749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.If approved, TEV-‘749 could help fill a significant unmet